Walentiny D Matthew, Vann Robert E, Wiley Jenny L
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Neuropharmacology. 2015 Jun;93:237-42. doi: 10.1016/j.neuropharm.2015.02.004. Epub 2015 Feb 16.
A number of studies have examined the ability of the endogenous cannabinoid anandamide to elicit Δ(9)-tetrahydrocannabinol (THC)-like subjective effects, as modeled through the THC discrimination paradigm. In the present study, we compared transgenic mice lacking fatty acid amide hydrolase (FAAH), the enzyme primarily responsible for anandamide catabolism, to wildtype counterparts in a THC discrimination procedure. THC (5.6 mg/kg) served as a discriminative stimulus in both genotypes, with similar THC dose-response curves between groups. Anandamide fully substituted for THC in FAAH knockout, but not wildtype, mice. Conversely, the metabolically stable anandamide analog O-1812 fully substituted in both groups, but was more potent in knockouts. The CB1 receptor antagonist rimonabant dose-dependently attenuated THC generalization in both groups and anandamide substitution in FAAH knockouts. Pharmacological inhibition of monoacylglycerol lipase (MAGL), the primary catabolic enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG), with JZL184 resulted in full substitution for THC in FAAH knockout mice and nearly full substitution in wildtypes. Quantification of brain endocannabinoid levels revealed expected elevations in anandamide in FAAH knockout mice compared to wildtypes and equipotent dose-dependent elevations in 2-AG following JZL184 administration. Dual inhibition of FAAH and MAGL with JZL195 resulted in roughly equipotent increases in THC-appropriate responding in both groups. While the notable similarity in THC's discriminative stimulus effects across genotype suggests that the increased baseline brain anandamide levels (as seen in FAAH knockout mice) do not alter THC's subjective effects, FAAH knockout mice are more sensitive to the THC-like effects of pharmacologically induced increases in anandamide and MAGL inhibition (e.g., JZL184).
许多研究通过Δ⁹-四氢大麻酚(THC)辨别范式,检验了内源性大麻素花生四烯乙醇胺引发类似THC主观效应的能力。在本研究中,我们在THC辨别程序中,将缺乏脂肪酸酰胺水解酶(FAAH,主要负责花生四烯乙醇胺分解代谢的酶)的转基因小鼠与野生型小鼠进行了比较。THC(5.6毫克/千克)在两种基因型中均作为辨别刺激物,两组之间的THC剂量反应曲线相似。花生四烯乙醇胺在FAAH基因敲除小鼠中能完全替代THC,但在野生型小鼠中则不能。相反,代谢稳定的花生四烯乙醇胺类似物O-1812在两组中都能完全替代THC,但在基因敲除小鼠中效力更强。CB1受体拮抗剂利莫那班在两组中均剂量依赖性地减弱THC泛化以及FAAH基因敲除小鼠中的花生四烯乙醇胺替代作用。用JZL184对单酰甘油脂肪酶(MAGL,内源性大麻素2-花生四烯酰甘油(2-AG)的主要分解代谢酶)进行药理学抑制,导致在FAAH基因敲除小鼠中能完全替代THC,在野生型小鼠中近乎完全替代。脑内源性大麻素水平的定量分析显示,与野生型相比,FAAH基因敲除小鼠中花生四烯乙醇胺水平预期升高,给予JZL184后2-AG呈现等效的剂量依赖性升高。用JZL195对FAAH和MAGL进行双重抑制,导致两组中对THC适当反应的增加大致等效。虽然THC的辨别刺激效应在不同基因型间有显著相似性,表明基线脑内花生四烯乙醇胺水平升高(如在FAAH基因敲除小鼠中所见)不会改变THC的主观效应,但FAAH基因敲除小鼠对药理学诱导的花生四烯乙醇胺增加和MAGL抑制(如JZL184)的类似THC效应更敏感。